经导管主动脉瓣植入术后感染性心内膜炎:全国性研究
该全国性注册研究纳入2008年至2018年中期共4336例TAVI患者,结合三个全国登记系统独立验证人工瓣膜心内膜炎(PVE)。TAVI后PVE第一年风险为1.4%(95%CI 1.0-1.8%),此后每年0.8%(0.6-1.1%);PVE诊断后1年生存率58%(49-68%),5年生存率29%(17-41%)。
要点
- TAVI后PVE年风险第一年1.4%,此后每年0.8%,与外科生物瓣相似。
- 肾功能受损(eGFR<30 mL/min/1.73 m2)是PVE的强危险因素。
- 金黄色葡萄球菌感染、根部脓肿、晚期PVE及非社区获得与6个月死亡率升高相关。
核心结论
- TAVI后PVE发生率与外科生物瓣相似,肾功能不全是发生PVE的强危险因素。
- 在PVE背景下,TAVI似乎是患者的安全选择。
研究设计与样本
- 全国性、全纳入研究,联合全国TAVI注册、诊断注册和感染性心内膜炎注册三个登记系统。
- 纳入2008年至2018年中期共4336例TAVI患者,PVE报告独立且经过验证。
主要发现
- TAVI后PVE第一年风险为1.4%(95%CI 1.0-1.8%),此后每年0.8%(0.6-1.1%)。
- PVE诊断后1年生存率58%(49-68%),5年生存率29%(17-41%)。
- 早期(<1年)PVE中金黄色葡萄球菌更常见。
- 金黄色葡萄球菌感染、根部脓肿、晚期PVE和非社区获得与6个月死亡率升高相关。
关键数值与推荐
- PVE独立危险因素包括:体表面积、eGFR<30 mL/min/1.73 m2、术前危重状态、术前平均瓣膜压差、使用的对比剂剂量、经心尖入路和心房颤动。
临床怎么用
- TAVI术后应关注PVE风险,尤其对肾功能不全(eGFR<30 mL/min/1.73 m2)等高危患者。
- 出现PVE时需注意金黄色葡萄球菌感染、根部脓肿、晚期PVE及非社区获得等预后不良因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Transcatheter aortic valve implantation (TAVI), now a common procedure to treat high-risk patients with severe aortic stenosis, has rapidly been expanding into younger and lower-risk populations, creating a need to better understand long-term outcome after TAVI. The aim of the present investigation was to determine the incidence, risk factors for, clinical presentation of, and outcome after prosthetic valve endocarditis (PVE) in patients treated with TAVI in a nationwide study. METHODS AND RESULTS: Three registries were used: a national TAVI registry, a national diagnosis registry, and a national infective endocarditis registry. Combining these registries made it possible to perform a nationwide, all-comers study with independent and validated reporting of PVE in 4336 patients between 2008 and mid-2018. The risk for PVE after TAVI was 1.4% (95% confidence interval 1.0-1.8%) the first year and 0.8% (0.6-1.1%) per year thereafter. One-year survival after PVE diagnosis was 58% (49-68%), and 5-year survival was 29% (17-41%). Body surface area, estimated glomerular filtration rate <30 mL/min/1.73 m2, critical pre-operative state, mean pre-procedural valve gradient, amount of contrast dye used, transapical access, and atrial fibrillation were identified as independent risk factors for PVE. Staphylococcus aureus was more common in early (<1 year) PVE. Infection with S. aureus, root abscess, late PVE, and non-community acquisition was associated with higher 6-month mortality. CONCLUSION: The incidence of PVE was similar to that of surgical bioprostheses. Compromised renal function was a strong risk factor for developing PVE. In the context of PVE, TAVI seems to be a safe option for patients. CLINICAL TRIAL REGISTRATION: NCT03768180 (http://clinicaltrials.gov/).
引用
- Bjursten H, Rasmussen M, Nozohoor S, et al. Infective endocarditis after transcatheter aortic valve implantation: a nationwide study. Eur Heart J. 2019. PMID: 31433472. doi:10.1093/eurheartj/ehz588
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。